D Clark Bennett

Title: D Clark Bennett: Innovator in Medical Enzymes

Introduction

D Clark Bennett is a notable inventor based in Pierrefonds, Canada. He has made significant contributions to the field of medical treatments through his innovative use of enzymes. With a total of 3 patents, his work focuses on reducing inflammatory responses and improving therapeutic methods.

Latest Patents

One of Bennett's latest patents involves the use of heparinases to decrease inflammatory responses. Heparinase enzymes can be utilized as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion, and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. Additionally, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium, are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit the accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.

Another significant patent by Bennett describes chondroitin lyase enzymes. This invention outlines a method for the production of two highly purified enzymes capable of degrading chondroitin sulfate polysaccharides. A multi-step purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography, hydroxylapatite chromatography, high-resolution ion exchange chromatography, and size exclusion is detailed. A 77,000 ± 5,000 Dalton protein capable of degrading chondroitin sulfates A and C and a 55,000 ± 2,300 Dalton protein capable of degrading dermatan sulfate were isolated. The genes encoding these enzymes, chondroitinase AC and chondroitinase B, respectively, have been cloned, and methods for their use are described.

Career Highlights

Throughout his career, D Clark Bennett has worked with reputable companies such as Ibex Technologies R and D, Inc. and BioMarin Pharmaceutical Inc. His experience in these organizations has contributed to his expertise in enzyme research and development.

Collaborations

Bennett has collaborated